{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:02:39Z","timestamp":1793646159527,"version":"4.5.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:28:26Z","timestamp":1751545706000},"page":"3336-3348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A history of the development of dual antiplatelet therapy for coronary artery disease"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-3279","authenticated-orcid":false,"given":"J.J.","family":"Coughlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Birrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Blackburne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.011_bib1","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/eurheartj\/ehae324","article-title":"Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease","volume":"45","author":"Patrono","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.011_bib2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","article-title":"A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction","volume":"1","author":"Elwood","year":"1974","journal-title":"Br Med J"},{"key":"10.1016\/j.jtha.2025.06.011_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib4","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","article-title":"Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) group","volume":"340","author":"Juul\u2013M\u00f6ller","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1056\/NEJM198801283180431","article-title":"Preliminary report: findings from the aspirin component of the ongoing Physicians\u2019 Health Study","volume":"318","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJM198804073181413","article-title":"aspirin for the primary prevention of myocardial infarction","volume":"318","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJM198001313020502","article-title":"Sulfinpyrazone in the prevention of sudden death after myocardial infarction","volume":"302","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib8","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina","volume":"313","author":"Cairns","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/bmj.4.5627.366","article-title":"Dipyridamole: a controlled trial of its effect in acute myocardial infarction","volume":"4","author":"Gent","year":"1968","journal-title":"Br Med J"},{"key":"10.1016\/j.jtha.2025.06.011_bib10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1161\/01.CIR.77.6.1324","article-title":"Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study","volume":"77","author":"Goldman","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.011_bib11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(81)92399-0","article-title":"Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome","volume":"1","author":"Telford","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM198010163031601","article-title":"Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction","volume":"303","author":"DeWood","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib13","series-title":"Ticlopidine, platelets and vascular disease","first-page":"13","article-title":"Overview of ticlopidine\u2019s development","author":"Panak","year":"1993"},{"key":"10.1016\/j.jtha.2025.06.011_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.crci.2012.05.006","article-title":"The story of clopidogrel and its predecessor, ticlopidine: could these major antiplatelet and antithrombotic drugs be discovered and developed today?","volume":"15","author":"Maffrand","year":"2012","journal-title":"C R Chim"},{"key":"10.1016\/j.jtha.2025.06.011_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.06.011_bib16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","article-title":"Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study","volume":"98","author":"Bertrand","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.011_bib18","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.011_bib19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.011_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib23","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.06.011_bib24","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib25","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","article-title":"Resistance to clopidogrel: a review of the evidence","volume":"45","author":"Nguyen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.06.011_bib28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcin.2010.12.011","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19\u22172 genotyping","volume":"4","author":"Alexopoulos","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jtha.2025.06.011_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/FJC.0b013e3182073dfb","article-title":"The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data","volume":"57","author":"Zhu","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.011_bib30","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(13)61451-8","article-title":"Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial","volume":"382","author":"Wiviott","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib33","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1016\/j.bmcl.2007.07.057","article-title":"From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis","volume":"17","author":"Springthorpe","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jtha.2025.06.011_bib34","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib35","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.011_bib36","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.011_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008649","article-title":"Randomized comparison of intensified and standard P2Y(12)-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial","volume":"13","author":"Mehilli","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jtha.2025.06.011_bib38","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(20)32236-4","article-title":"Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomized, open-label, phase 3b trial","volume":"396","author":"Silvain","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib39","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib40","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.06.011_bib41","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib42","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib43","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.011_bib44","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.011_bib46","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jcin.2017.03.049","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for DES after discontinuation of clopidogrel)","volume":"10","author":"Didier","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jtha.2025.06.011_bib47","first-page":"894","article-title":"Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation","volume":"75","author":"Coughlan","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jtha.2025.06.011_bib48","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz\u2013Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.011_bib49","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2025.06.011_bib50","doi-asserted-by":"crossref","first-page":"B1","DOI":"10.1093\/eurheartj\/sux041","article-title":"Bleeding on dual antiplatelet therapy: real-life challenges","volume":"20","author":"Deshpande","year":"2018","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jtha.2025.06.011_bib51","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.06.011_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jtha.2025.06.011_bib53","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.06.011_bib54","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib55","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomized, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib56","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib57","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomized, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib58","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib59","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib60","doi-asserted-by":"crossref","first-page":"f50","DOI":"10.1093\/ehjcvp\/pvaa116","volume":"7","author":"Gargiulo","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jtha.2025.06.011_bib61","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.011_bib62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.011_bib63","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.011_bib64","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib65","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib66","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjcard.2003.11.048","article-title":"Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention","volume":"93","author":"Quinn","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2025.06.011_bib67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.amjcard.2004.04.035","article-title":"Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention","volume":"94","author":"Vivekananthan","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2025.06.011_bib68","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11886-020-01439-2","article-title":"Update on the inflammatory hypothesis of coronary artery disease","volume":"23","author":"Boland","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jtha.2025.06.011_bib69","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.011_bib70","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.011_bib71","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.amjcard.2006.04.034","article-title":"Impact of percutaneous coronary intervention on the levels of interleukin-6 and C-reactive protein in the coronary circulation of subjects with coronary artery disease","volume":"98","author":"Ramadan","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2025.06.011_bib72","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/eurheartj\/ehz917","article-title":"Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study","volume":"41","author":"Schnorbus","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.011_bib73","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.amjcard.2023.06.036","article-title":"Bleeding and ischemic risk prediction in patients with high bleeding risk (an EVOLVE short DAPT analysis)","volume":"207","author":"Mihatov","year":"2023","journal-title":"Am J Cardiol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:28:10Z","timestamp":1758950890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625003940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1538783625003940"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.011","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A history of the development of dual antiplatelet therapy for coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}